What question did this study set out to answer?

Assess the cardioprotective efficacy, antitumor impact, and safety profile of dexrazoxane in pediatric patients treated with doxorubicin-containing regimens for T-cell leukemia or lymphoma.

December 23, 2015Journal of Clinical Oncology

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404

View Full Paper

Ask AI

Bookmark

Why the study?

Does dexrazoxane provide cardioprotection without compromising safety or efficacy in children and adolescents treated with doxorubicin-containing chemotherapy for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma?

Population

Children and adolescents treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage…

Design

RCT

Authors

BABarbara L. AsselinUniversity of Rochester Medical Center MDMeenakshi DevidasChildren's Oncology Group LCLu ChenShanghai Sixth People's Hospital

Discussion

Member takes

Implication

Supports dexrazoxane for cardioprotection in pediatric doxorubicin regimens; confirms safety and efficacy in T-cell ALL/NHL.

Key Points

Assess the cardioprotective efficacy, antitumor impact, and safety profile of dexrazoxane in pediatric patients treated with doxorubicin-containing regimens for T-cell leukemia or lymphoma.
Conducted a randomized trial (Pediatric Oncology Group 9404) through the Children's Oncology Group in children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma.
Evaluated the addition of dexrazoxane as a cardioprotectant alongside a doxorubicin-containing chemotherapy regimen.
Dexrazoxane provided cardioprotection while maintaining full antitumor chemotherapy efficacy.
Administration of dexrazoxane did not increase general toxicity rates and showed no significant association with secondary malignancies.

Structured PICO

Population

Children and adolescents treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma receiving a doxorubicin-containing chemotherapy regimen

Intervention

Dexrazoxane

Outcome

Cardioprotection, antitumor efficacy, toxicities, and second malignanciessafety

Dexrazoxane safely provides cardioprotection without compromising antitumor efficacy in pediatric patients receiving anthracycline-based chemotherapy.

Cite This Study

Asselin et al. (2015) studied this question.

synapsesocial.com/papers/69d57641c23ff40c2825de29 https://doi.org/10.1200/jco.2015.60.8851

Topics

Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider